Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

The legacy of FASENRA® (benralizumab injection) across two indications

Over 8 years of experience in Canada2*

Authorized in 80 countries3*

15 years of clinical trial experience3*

Studied in >10,000 patients in clinical trials3*

FASENRA® was authorized for use in severe eosinophilic asthma in 2018 and for EGPA in 2025.

Be the first to receive the latest news and clinical information on FASENRA®.

Safety information

Clinical use:

 

FASENRA® is not indicated for other eosinophilic conditions or for relief of acute bronchospasm or status asthmaticus.

FASENRA® is not indicated in the pediatric population, as the efficacy and safety of FASENRA® has not been established in patients less than 18 years of age.

There is limited experience with FASENRA® in patients 65 years of age and older. No overall differences in efficacy or safety of FASENRA® were observed between geriatric and adult patients treated with FASENRA® in clinical trials. Sensitivity of some older individuals, however, cannot be excluded.

 

Relevant warnings and precautions:

 

  • FASENRA® should not be used to treat acute asthma symptoms or exacerbations
  • Abrupt corticosteroid discontinuation is not recommended
  • Need for gradual reduction in corticosteroid doses
  • Helminth infection
  • Hypersensitivity reactions and administration-related reactions
  • Pregnant and nursing women

 

For more information:

 

Please consult the Product Monograph for important information regarding adverse reactions, drug interactions, and dosing instructions which have not been discussed in the piece. The Product Monograph is also available by calling 1-800-668-6000.

* Clinical significance unknown.

 

References:

 

  1. FASENRA® Product Monograph, AstraZeneca Canada Inc.
  2. FASENRA® Notice of Compliance. 2018.
  3. Data on file. AstraZeneca Canada Inc.

CA-12203E